These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34153688)

  • 21. Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients.
    Yang Z; Cummings JL; Kinney JW; Cordes D;
    Front Neurosci; 2023; 17():1151820. PubMed ID: 37123373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
    Womack KB; Diaz-Arrastia R; Aizenstein HJ; Arnold SE; Barbas NR; Boeve BF; Clark CM; DeCarli CS; Jagust WJ; Leverenz JB; Peskind ER; Turner RS; Zamrini EY; Heidebrink JL; Burke JR; DeKosky ST; Farlow MR; Gabel MJ; Higdon R; Kawas CH; Koeppe RA; Lipton AM; Foster NL
    Arch Neurol; 2011 Mar; 68(3):329-37. PubMed ID: 21059987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
    Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
    Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization.
    Bergeron D; Sellami L; Poulin S; Verret L; Bouchard RW; Laforce R
    Dement Geriatr Cogn Disord; 2020; 49(5):518-525. PubMed ID: 33207355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity.
    Phillips ML; Stage EC; Lane KA; Gao S; Risacher SL; Goukasian N; Saykin AJ; Carrillo MC; Dickerson BC; Rabinovici GD; Apostolova LG;
    Dement Geriatr Cogn Disord; 2019; 48(3-4):131-142. PubMed ID: 31901905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG PET imaging in patients with pathologically verified dementia.
    Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
    J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posterior Cingulate Cortex Hypometabolism in Non-Amnestic Variants of Alzheimer's Disease.
    Bergeron D; Beauregard JM; Soucy JP; Verret L; Poulin S; Matias-Guiu JA; Cabrera-Martín MN; Bouchard RW; Laforce R
    J Alzheimers Dis; 2020; 77(4):1569-1577. PubMed ID: 32925054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration.
    Levin F; Ferreira D; Lange C; Dyrba M; Westman E; Buchert R; Teipel SJ; Grothe MJ;
    Alzheimers Res Ther; 2021 Feb; 13(1):49. PubMed ID: 33608059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia.
    Frings L; Spehl TS; Weber WA; Hüll M; Meyer PT
    J Nucl Med; 2013 Nov; 54(11):1909-14. PubMed ID: 24101684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain metabolic signatures across the Alzheimer's disease spectrum.
    Sala A; Caprioglio C; Santangelo R; Vanoli EG; Iannaccone S; Magnani G; Perani D
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):256-269. PubMed ID: 31811345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
    Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
    Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage.
    Morbelli S; Bauckneht M; Arnaldi D; Picco A; Pardini M; Brugnolo A; Buschiazzo A; Pagani M; Girtler N; Nieri A; Chincarini A; De Carli F; Sambuceti G; Nobili F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2073-2083. PubMed ID: 28785843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
    Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Chételat G; Ossenkoppele R; Villemagne VL; Perrotin A; Landeau B; Mézenge F; Jagust WJ; Dore V; Miller BL; Egret S; Seeley WW; van der Flier WM; La Joie R; Ames D; van Berckel BN; Scheltens P; Barkhof F; Rowe CC; Masters CL; de La Sayette V; Bouwman F; Rabinovici GD
    Brain; 2016 Sep; 139(Pt 9):2528-39. PubMed ID: 27357349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?
    Teipel S; Grothe MJ;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):526-36. PubMed ID: 26555082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease.
    Gatchel JR; Donovan NJ; Locascio JJ; Becker JA; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Am J Geriatr Psychiatry; 2017 Jul; 25(7):683-693. PubMed ID: 28410856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.
    Isella V; Crivellaro C; Formenti A; Musarra M; Pacella S; Morzenti S; Ferri F; Mapelli C; Gallivanone F; Guerra L; Appollonio I; Ferrarese C
    J Neurol; 2022 Aug; 269(8):4440-4451. PubMed ID: 35347453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.
    Lehmann M; Ghosh PM; Madison C; Laforce R; Corbetta-Rastelli C; Weiner MW; Greicius MD; Seeley WW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2013 Mar; 136(Pt 3):844-58. PubMed ID: 23358601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.